Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
|
|
Celldex Therapeutics, Inc. (CLDX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 10.1% stake in Celldex Therapeutics, Inc. |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/21/2023 |
8-K
| Other Events Interactive Data |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 0% stake in Celldex Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/06/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/01/2023 |
SC 13G/A
| STATE STREET CORP reports a 4.9% stake in EXIT FILING CELLDEX THERAPEUTICS INC |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 08/19/2022 |
4
| Cavanaugh Sarah (SVP OF CORP AFFAIRS & ADMIN.) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Sold 31,312 shares
@ $36.7342, valued at
$1.2M
Sold 1,355 shares
@ $36.3757, valued at
$49.3k
Exercised 31,312 options to buy
@ $2.78, valued at
$87k
Exercised 1,355 options to buy
@ $9.0165, valued at
$12.2k
|
|
| 08/19/2022 |
4
| Young Diane C. (SVP, CHIEF MEDICAL OFFICER) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Sold 19,000 shares
@ $37.3008, valued at
$708.7k
Exercised 19,000 options to buy
@ $10.38, valued at
$197.2k
Exercised 45,000 options to buy
@ $2.71, valued at
$122k
|
|
| 08/17/2022 |
4
| Marucci Anthony S (PRESIDENT & CEO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Exercised 45,000 shares
@ $9.0165, valued at
$405.7k
Sold 120,000 shares
@ $37.6631, valued at
$4.5M
Exercised 75,000 options to buy
@ $2.78, valued at
$208.5k
Exercised 45,000 options to buy
@ $0 |
|
| 08/17/2022 |
4
| Wright Richard M. (SR. VP & CCO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Sold 15,328 shares
@ $37.7119, valued at
$578k
Exercised 15,328 options to buy
@ $10.38, valued at
$159.1k
|
|
| 08/15/2022 |
4
| Martin Samuel Bates (SVP AND CFO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Sold 2,453 shares
@ $37.0389, valued at
$90.9k
Sold 14,261 shares
@ $36.7649, valued at
$524.3k
Sold 2,065 shares
@ $35.3766, valued at
$73.1k
Sold 1,221 shares
@ $34.6206, valued at
$42.3k
Exercised 2,453 options to buy
@ $9.0165, valued at
$22.1k
Exercised 3,876 options to buy
@ $9.0165, valued at
$34.9k
Exercised 13,671 options to buy
@ $2.78, valued at
$38k
|
|
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 07/18/2022 |
8-K
| Quarterly results |
| 06/23/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
4
| Wright Richard M. (SR. VP & CCO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Granted 42,000 options to buy
@ $22.48, valued at
$944.2k
|
|
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Cavanaugh Sarah (SVP OF CORP AFFAIRS & ADMIN.) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Granted 73,000 options to buy
@ $22.48, valued at
$1.6M
|
|
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Young Diane C. (SVP, CHIEF MEDICAL OFFICER) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Granted 76,000 options to buy
@ $22.48, valued at
$1.7M
|
|
| 06/17/2022 |
4
| Crowley Elizabeth (SR. VP &CPDO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Granted 77,000 options to buy
@ $22.48, valued at
$1.7M
|
|
| 06/17/2022 |
4
| Martin Samuel Bates (SVP AND CFO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Granted 85,000 options to buy
@ $22.48, valued at
$1.9M
|
|
| 06/17/2022 |
4
| PEPIN RONALD (SR. VP & CBO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $22.48, valued at
$337.2k
|
|
| 06/17/2022 |
4
| KELER TIBOR (EXECUTIVE VP & CSO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Granted 91,000 options to buy
@ $22.48, valued at
$2M
|
|
|
|
|